You are on page 1of 6

.

LPL - PSC SAROJ DIAGNOSTIC


CENTRE
70/6, Yusuf Sarai Market, New
Delhi 110016, Ph :
011-41640132

Name

: Baby DIYA ARAVIND

Lab No.

: 222690169

Age: 7 Years

A/c Status

: P

Ref By :

Gender:

aiims

Test Name

Female

Collected
Received
Reported

: 29/8/2015 12:01:00PM
: 29/8/2015 12:01:10PM
: 31/8/2015 9:52:30AM

Report Status

: Final

Results

Units

Bio. Ref. Interval

Cholesterol Total

273.00

mg/dL

<170.00

Triglycerides

388.00

mg/dL

<150.00

HDL Cholesterol

53.00

mg/dL

40.00 - 60.00

LDL Cholesterol

142.40

mg/dL

<110.00

VLDL Cholesterol

77.60

mg/dL

<30.00

Non-HDL Cholesterol

220.00

mg/dL

LIPID PROFILE, BASIC, SERUM


(Spectrophotometry, Calculated)

Interpretation
-------------------------------------------------------------------| NCEP
| TOTAL
| TRIGLYCERIDE | LDL CHOLESTEROL |
| RECOMMENDATIONS
| CHOLESTEROL
| in mg/dL
| in mg/dL
|
|
| in mg/dL
|
|
|
|-------------------|---------------|--------------|-----------------|
| Optimal
| <170
| <150
| <110
|
|-------------------|---------------|--------------|-----------------|
| Borderline High
| 171-199
| 150-199
| 111-129
|
|-------------------|---------------|--------------|-----------------|
| High
| >=200
| 200-499
| >=130
|
|-------------------|---------------|--------------|-----------------|
| Very High
| | >=500
| |
--------------------------------------------------------------------

Note

1. Measurements in the same patient can show physiological & analytical variations. Three serial samples
1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
2. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status.
Selective screening of children above the age of 2 years with a family history of premature
cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
3. NCEP identifies elevated Triglycerides as an independent risk factor for Coronary Heart Disease (CHD).
4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to
participate in reverse cholesterol transport, the process by which cholesterol is eliminated from
peripheral tissues.
5. ATP III guidelines uses LDL Cholesterol as the primary target for cholesterol lowering therapy. Note that
major risk factors can modify LDL goals.
NON HDL CHOLESTEROL
----------------------------------------------------------------------| RISK CATEGORY
| LDL GOAL ( mg/dL)
| NON HDL GOAL ( mg/dL)|
|----------------------|-------------------------|----------------------|
| CHD & CHD risk
| < 100
| < 130
|
| equivalent (10 year |
|
|
| risk for CHD > 20 %) |
|
|
----------------------------------------------------------------------|----------------------|-------------------------|----------------------|
| Multiple (2+) Risk
| < 130
| < 160
|
PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 4)

Page 1 of 6

.
LPL - PSC SAROJ DIAGNOSTIC
CENTRE
70/6, Yusuf Sarai Market, New
Delhi 110016, Ph :
011-41640132

Name

: Baby DIYA ARAVIND

Lab No.

: 222690169

Age: 7 Years

A/c Status

: P

Ref By :

Gender:

aiims

Female

Collected
Received
Reported

: 29/8/2015 12:01:00PM
: 29/8/2015 12:01:10PM
: 31/8/2015 9:52:30AM

Report Status

: Final

Test Name
Results
Units
| Factors and 10 year |
|
|
| risk < or = 20%
|
|
|
|----------------------|-------------------------|----------------------|
| 0-1 Risk factor
| < 160
| <190
|
-----------------------------------------------------------------------

Bio. Ref. Interval

Comment:

ATP III suggested the addition of Non HDL Cholesterol


all atherogenic lipoproteins ( Mainly LDL & VLDL). The
therapy in persons with triglycerides >=200 mg/dL. The
triglyceride is 30 mg/dL above that set for LDL Cholesterol.
For calculation of CHD risk, history of smoking, any
levels are required.

(Total Cholesterol - HDL Cholesterol) as an indicator of


Non HDL Cholesterol is used as a secondary target of
goal for Non HDL Cholesterol in those with increased
medication for hypertension & current blood pressure

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 4)

Page 2 of 6

.
LPL - PSC SAROJ DIAGNOSTIC
CENTRE
70/6, Yusuf Sarai Market, New
Delhi 110016, Ph :
011-41640132

Name

Baby DIYA ARAVIND

Lab No.

222690169

Age: 7 Years

A/c Status

Ref By :

Gender:

Female

aiims

Test Name

Results

Collected
Received
Reported

: 29/8/2015 12:01:00PM
: 29/8/2015 12:01:10PM
: 31/8/2015 9:52:33AM

Report Status

: Final

Units

Bio. Ref. Interval

CREATININE, 24-HOUR URINE


(Compensated Jaffe's reaction, IDMS traceable)

Creatinine, 24 Hour

9.10

mg/kg/day

8.00 - 22.00

Total Urine volume

750

mL/day

650.00 - 1000.00

Body weight

15

kg

Total Protein

0.66

g/day

0.04 - 0.15

Total Urine Volume

750

mL/day

650.00 - 1000.00

PROTEIN, TOTAL, 24-HOUR URINE


(Spectrophotometry)

Interpretation
------------------------------------------| STATE
| RESULT IN g/day
|
|----------------|--------------------------|
| At rest
| 0.04 - 0.15
|
|----------------|--------------------------|
| After exercise | <0.25
|
-------------------------------------------

Note

1. Excretion of total protein in individuals is highly variable with or without kidney disease.
2. Conditions affecting protein excretion other than kidney disease are urinary tract infection, diet,
menstruation & physical activity
Comments

Diagnosis of kidney disease and response to therapy is usually obtained by quantitatively analyzing the
amount of protein excreted in urine over a 24 hour period.
-----------------------------------------------------------| TYPES OF
| TOTAL PROTEIN IN | CONDITIONS
|
| PROTEINURIA | g /day
|
|
|-------------|------------------|---------------------------|
| Heavy
| >4
| Nephrotic syndrome, Acute |
|
|
| Rapidly Progressive &
|
|
|
| Chronic
|
|
|
| Glomerulonephritis,
|
|
|
| Diabetes mellitus, Lupus |
|
|
| erythematosus, Drugs like |
|
|
| Penicillamine, Heavy
|
|
|
| metals like Gold & Mercury|
|-------------|------------------|---------------------------|
| Moderate
| 1-4
| Nephrosclerosis, Multiple |
|
|
| myeloma, Toxic
|
|
|
| nephropathies, Renal
|
|
|
| calculi
|
|-------------|------------------|---------------------------|
| Minimal
| <1
| Chronic pyelonephritis,
|
|
|
| Chronic interstitial
|
|
|
| nephritis, Renal tubular |
|
|
| diseases, Postural
|
PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 5)

Page 3 of 6

.
LPL - PSC SAROJ DIAGNOSTIC
CENTRE
70/6, Yusuf Sarai Market, New
Delhi 110016, Ph :
011-41640132

Name

Baby DIYA ARAVIND

Lab No.

222690169

Age: 7 Years

A/c Status

Ref By :

Gender:

Female

aiims

Test Name
Results
------------------------------------------------------------

Collected
Received
Reported

: 29/8/2015 12:01:00PM
: 29/8/2015 12:01:10PM
: 31/8/2015 9:52:33AM

Report Status

: Final

Units

Bio. Ref. Interval

CD19
(Flow Cytometry-Single platform bead assay)

Absolute Lymphocyte Count

901

/uL

660.00 - 4600.00

CD19 (Total B cells)

<1.0

13.00 - 27.00

Absolute CD19

<5.0

/uL

270.00 - 860.00

Note

1. Test conducted on EDTA / Heparin whole blood. ACD samples not accepted
2. CD19 counts increase between 8.30 am to 12 noon
3. Gating strategy is CD45 vs SSC

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 5)

Page 4 of 6

.
LPL - PSC SAROJ DIAGNOSTIC
CENTRE
70/6, Yusuf Sarai Market, New
Delhi 110016, Ph :
011-41640132

Name

Baby DIYA ARAVIND

Lab No.

222690169

Age: 7 Years

A/c Status

Ref By :

Gender:

Female

aiims

Collected
Received
Reported

: 29/8/2015 12:01:00PM
: 29/8/2015 12:01:10PM
: 31/8/2015 9:52:36AM

Report Status

: Final

Test Name

Results

Units

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD


(HPLC, NGSP certified)

4.70

Bio. Ref. Interval

Interpretation
------------------------------------------------------------------------------|
As per American Diabetes Association (ADA)
|
|-------------------------------------------------------------------------------|
| Reference Group
| HbA1c in %
|
|-------------------------------|-----------------------------------------------|
| Non diabetic adults >=18 years| <5.7
|
|-------------------------------|-----------------------------------------------|
| At risk (Prediabetes)
| 5.7 - 6.4
|
|-------------------------------|-----------------------------------------------|
| Diagnosing Diabetes
| >= 6.5
|
|-------------------------------|-----------------------------------------------|
| Therapeutic goals for glycemic| Age > 19 years
|
| control
| . Goal of therapy: < 7.0
|
|
| . Action suggested: > 8.0
|
|
|
|
|
| Age < 19 years
|
|
| . Goal of therapy: <7.5
|
-------------------------------------------------------------------------------

Note: 1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a

diabetic patient who is recently under good control may still have a high concentration of
HbA1c. Converse is true for a diabetic previously under good control but now poorly
controlled .
2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long
life expectancy and no significant cardiovascular disease. In patients with significant
complications of diabetes, limited life expectancy or extensive co-morbid conditions,
targeting a goal of < 7.0 % may not be appropriate.
Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better
indicator of long term glycemic control as compared to blood and urinary glucose determinations.
ADA criteria for correlation between HbA1c & Mean plasma glucose levels
--------------------------------------| HbA1c(%) | Mean Plasma Glucose (mg/dL)|
|----------|----------------------------|
| 6
| 126
|
|----------|----------------------------|
| 7
| 154
|
|----------|----------------------------|
| 8
| 183
|
|----------|----------------------------|
| 9
| 212
|
PatientReportSCSuperPanel.HBELECTRO_SC (Version: 5)

Page 5 of 6

.
LPL - PSC SAROJ DIAGNOSTIC
CENTRE
70/6, Yusuf Sarai Market, New
Delhi 110016, Ph :
011-41640132

Name

Baby DIYA ARAVIND

Lab No.

222690169

Age: 7 Years

A/c Status

Ref By :

Test Name

Gender:

Female

aiims

Results
|----------|----------------------------|
| 10
| 240
|
|----------|----------------------------|
| 11
| 269
|
|----------|----------------------------|
| 12
| 298
|
---------------------------------------

Dr Beena Chandrasekhar
PhD (Life Sciences)
HOD Flowcytometry

Dr Onjal Taywade
MD (Biochemistry)
Consultant Biochemist

Collected
Received
Reported

: 29/8/2015 12:01:00PM
: 29/8/2015 12:01:10PM
: 31/8/2015 9:52:36AM

Report Status

: Final

Units

Bio. Ref. Interval

Dr. Sushrut Pownikar


DNB (Pathology)
HOD Hemat & Imm

-------------------------------End of report --------------------------------

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 5)

Page 6 of 6

You might also like